Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: acesulfame potassium; mannitol; sodium stearylfumarate; hypromellose; colloidal anhydrous silica; ethylcellulose; crospovidone; silicon dioxide; flavour - for acute treatment of migraine attacks with or without aura.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; colloidal anhydrous silica; crospovidone; magnesium stearate; mannitol; microcrystalline cellulose; calcium silicate; flavour - rizalt is indicated for the acute treatment of migraine attacks with or without aura.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: copovidone; simethicone; purified talc; glyceryl monostearate; stearic acid; polysorbate 80; titanium dioxide; colloidal anhydrous silica; propylene glycol; macrogol 6000; hypromellose; microcrystalline cellulose; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; crospovidone; iron oxide red; sucrose; hydrolysed maize starch; maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; propylene glycol; simethicone; stearic acid; macrogol 6000; crospovidone; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; copovidone; polysorbate 80; hypromellose; purified talc; povidone; iron oxide red; maize starch; sucrose; hydrolysed maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: hyprolose; croscarmellose sodium; iron oxide red; magnesium stearate; hypromellose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 5.2 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - alendronate sodium, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; macrogol 8000; carrageenan; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: gelatin; croscarmellose sodium; butylated hydroxytoluene; colloidal anhydrous silica; sucrose; magnesium stearate; microcrystalline cellulose; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; gelatin; croscarmellose sodium; medium chain triglycerides; microcrystalline cellulose; magnesium stearate; sucrose; butylated hydroxytoluene - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture